The Value of International Staging System in Predicting Survival of Multiple Myeloma Patients With Renal Failure

Tuğçe Nur Yiğenoğlu; Semih Başcı; Mehmet Bakırtaş

doi:10.5798/dicletip.748566

The Value of International Staging System in Predicting Survival of Multiple Myeloma Patients With Renal Failure

Abstract

Objectives: At the time of diagnosis, 20 to 30% of multiple myeloma (MM) patients have renal failure. International Staging System (ISS) is based on 2 variables: serum levels of albumin and beta 2-microglobulin (B2M). Serum B2M level increases in patients with renal failure. This means that the elevated serum level of B2M is not always correlated with tumor burden in MM patients who have renal failure. Therefore, these patients may have further ISS stages than they really have. In this study, we aim to evaluate the success of ISS in predicting survival in MM patients with renal failure.
Method: The data of 172 MM patients that underwent autologous stem cell transplantation (ASCT) at our center were retrospectively analyzed. The patients were divided into 5 renal function stages according to the Renal Disease Quality Classification of the National Kidney Foundation.
Results: Overall survival (OS) after ASCT was found 21 months in ISS1 patients, 20 months in ISS2 patients, and 18 months in ISS3 patients. OS in stage 0-1 patients was 18 months, it was 30 months in stage 2-3-4-5 patients. There was no statistically significant difference regarding OS between patients with renal failure and normal renal function in all ISS stages.
Conclusion: Our data reveals that the significance of ISS to predict overall survival is independent from renal failure.

Keywords

Multipl myeloma

References

1. Rajkumar V. Multiple Myeloma. Curr Probl Cancer 2009; 33: 7–64.
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–20.
3. Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009; 23: 1152–7.
4. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–20.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Authors

Tuğçe Nur Yiğenoğlu ^* This is me
Türkiye

Semih Başcı ^* This is me
Türkiye

Mehmet Bakırtaş This is me
Türkiye

Publication Date

June 17, 2020

Submission Date

January 23, 2020

Acceptance Date

May 4, 2020

Published in Issue

Year 2020 Volume: 47 Number: 2

DOI

https://doi.org/10.5798/dicletip.748566

IZ

https://izlik.org/JA96JA28CH

Cite

RIS / Bibtex

APA

Yiğenoğlu, T. N., Başcı, S., & Bakırtaş, M. (2020). The Value of International Staging System in Predicting Survival of Multiple Myeloma Patients With Renal Failure. Dicle Medical Journal, 47(2), 237-242. https://doi.org/10.5798/dicletip.748566

AMA

1.Yiğenoğlu TN, Başcı S, Bakırtaş M. The Value of International Staging System in Predicting Survival of Multiple Myeloma Patients With Renal Failure. Dicle Medical Journal. 2020;47(2):237-242. doi:10.5798/dicletip.748566

Chicago

Yiğenoğlu, Tuğçe Nur, Semih Başcı, and Mehmet Bakırtaş. 2020. “The Value of International Staging System in Predicting Survival of Multiple Myeloma Patients With Renal Failure”. Dicle Medical Journal 47 (2): 237-42. https://doi.org/10.5798/dicletip.748566.

EndNote

Yiğenoğlu TN, Başcı S, Bakırtaş M (June 1, 2020) The Value of International Staging System in Predicting Survival of Multiple Myeloma Patients With Renal Failure. Dicle Medical Journal 47 2 237–242.

IEEE

[1]T. N. Yiğenoğlu, S. Başcı, and M. Bakırtaş, “The Value of International Staging System in Predicting Survival of Multiple Myeloma Patients With Renal Failure”, Dicle Medical Journal, vol. 47, no. 2, pp. 237–242, June 2020, doi: 10.5798/dicletip.748566.

ISNAD

Yiğenoğlu, Tuğçe Nur - Başcı, Semih - Bakırtaş, Mehmet. “The Value of International Staging System in Predicting Survival of Multiple Myeloma Patients With Renal Failure”. Dicle Medical Journal 47/2 (June 1, 2020): 237-242. https://doi.org/10.5798/dicletip.748566.

JAMA

1.Yiğenoğlu TN, Başcı S, Bakırtaş M. The Value of International Staging System in Predicting Survival of Multiple Myeloma Patients With Renal Failure. Dicle Medical Journal. 2020;47:237–242.

MLA

Yiğenoğlu, Tuğçe Nur, et al. “The Value of International Staging System in Predicting Survival of Multiple Myeloma Patients With Renal Failure”. Dicle Medical Journal, vol. 47, no. 2, June 2020, pp. 237-42, doi:10.5798/dicletip.748566.

Vancouver

1.Tuğçe Nur Yiğenoğlu, Semih Başcı, Mehmet Bakırtaş. The Value of International Staging System in Predicting Survival of Multiple Myeloma Patients With Renal Failure. Dicle Medical Journal. 2020 Jun. 1;47(2):237-42. doi:10.5798/dicletip.748566